TriangleSacituzumab govitecan (NCT05838521)
Sacituzumab govitecan trial for Cervical Cancer (NCT05838521). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with recurrent or persistent epithelial cervical cancer that progressed after chemotherapy. Prior chemotherapy given only with primary radiation does not count. Recurrent disease permits at most two chemotherapy regimens; previous topoisomerase-I inhibitors are excluded.
The idea: sacituzumab govitecan carries SN-38 to TROP-2-bearing cells, disrupting DNA copying. Treatment is given during the first two weeks of each three-week cycle until progression or unacceptable toxicity. Stored tumor tissue is required for TROP-2 testing.
This phase 2 study plans 20 patients. Alessandro Santin leads at Yale; two US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.